Market Cap 38.63M
Revenue (ttm) 3.09M
Net Income (ttm) -7.36M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 8.15
Profit Margin -238.19%
Debt to Equity Ratio 0.00
Volume 122,800
Avg Vol 395,200
Day's Range N/A - N/A
Shares Out 36.44M
Stochastic %K 2%
Beta 1.15
Analysts Strong Sell
Price Target $6.00

Company Profile

Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large...

Industry: Biotechnology
Sector: Healthcare
Phone: 561 743 8333
Fax: 561 743 8343
Address:
1044 North U.S. Highway One, Suite 201, Jupiter, United States
B2iDigital
B2iDigital Jul. 27 at 9:32 PM
Genvor, Inc. (OTCQB: $GNVR), a biotechnology company harnessing AI to generate novel peptides, said its proprietary antimicrobial peptides are being evaluated for their potential to address microbial challenges in sugar beet production, under the USDA Agricultural Research Service (ARS) Sustainable Sugar Beet Research Initiative. Genvor is a @B2iDigital Featured Company. See the company's profile at https://b2idigital.com/genvor-incorporated-1 As a collaborator, the company is contributing its antimicrobial peptides for evaluation against key sugar beet microbial targets: • USDA-ARS researchers will evaluate whether Genvor's antimicrobial peptides can inhibit key microbes involved in sugar beet root rot and in downstream sugar extraction • The work may generate data to inform future peptide-based crop protection strategies "Our work with collaborators has consistently demonstrated how much peptide science can contribute to agriculture," said Dr. Jesse Jaynes, Co-Founder of Genvor and the founding scientist behind the company's core peptide technologies. "Extending that collaboration into sugar beet lets us apply our peptides to a new set of microbial targets and continue advancing the design work that makes these tools more effective." Read the full release: https://genvor.com/press-releases/post?storyId=6174274901791168 Genvor, Inc. (OTCQB: GNVR) is a biotechnology company harnessing AI to generate novel peptides that deliver high-performance solutions across agriculture and human health. Powered by its proprietary BioCypher platform and patented peptides, Genvor is developing and intends to commercialize biological actives for crop protection and plant health alongside consumer-focused peptide solutions for recovery, performance, anti-aging, and daily wellness. Learn more at https://www.genvor.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted GNVR stock, in line with B2i Digital's practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $EVGN $PTN $RKDA $DYAI
1 · Reply
B2iDigital
B2iDigital Jul. 27 at 6:25 PM
Genvor, Inc. (OTCQB: $GNVR), a biotechnology company harnessing AI to generate novel peptides, said its proprietary antimicrobial peptides are being evaluated for their potential to address microbial challenges in sugar beet production, under the USDA Agricultural Research Service (ARS) Sustainable Sugar Beet Research Initiative. Genvor is a @B2iDigital Featured Company. See the company's profile at https://b2idigital.com/genvor-incorporated-1 As a collaborator, the company is contributing its antimicrobial peptides for evaluation against key sugar beet microbial targets: • USDA-ARS researchers will evaluate whether Genvor's antimicrobial peptides can inhibit key microbes involved in sugar beet root rot and in downstream sugar extraction • The work may generate data to inform future peptide-based crop protection strategies "Our work with collaborators has consistently demonstrated how much peptide science can contribute to agriculture," said Dr. Jesse Jaynes, Co-Founder of Genvor and the founding scientist behind the company's core peptide technologies. "Extending that collaboration into sugar beet lets us apply our peptides to a new set of microbial targets and continue advancing the design work that makes these tools more effective." Read the full release: https://genvor.com/press-releases/post?storyId=6174274901791168 Genvor, Inc. (OTCQB: GNVR) is a biotechnology company harnessing AI to generate novel peptides that deliver high-performance solutions across agriculture and human health. Powered by its proprietary BioCypher platform and patented peptides, Genvor is developing and intends to commercialize biological actives for crop protection and plant health alongside consumer-focused peptide solutions for recovery, performance, anti-aging, and daily wellness. Learn more at https://www.genvor.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted GNVR stock, in line with B2i Digital's practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $EVGN $PTN $RKDA $DYAI
1 · Reply
B2iDigital
B2iDigital Jul. 27 at 2:59 PM
Genvor, Inc. (OTCQB: $GNVR ), a biotechnology company harnessing AI to generate novel peptides, said its proprietary antimicrobial peptides are being evaluated for their potential to address microbial challenges in sugar beet production, under the USDA Agricultural Research Service (ARS) Sustainable Sugar Beet Research Initiative. Genvor is a @B2iDigital Featured Company. See the company's profile at https://b2idigital.com/genvor-incorporated-1 As a collaborator, the company is contributing its antimicrobial peptides for evaluation against key sugar beet microbial targets: • USDA-ARS researchers will evaluate whether Genvor's antimicrobial peptides can inhibit key microbes involved in sugar beet root rot and in downstream sugar extraction • The work may generate data to inform future peptide-based crop protection strategies "Our work with collaborators has consistently demonstrated how much peptide science can contribute to agriculture," said Dr. Jesse Jaynes, Co-Founder of Genvor and the founding scientist behind the company's core peptide technologies. "Extending that collaboration into sugar beet lets us apply our peptides to a new set of microbial targets and continue advancing the design work that makes these tools more effective." Read the full release: https://genvor.com/press-releases/post?storyId=6174274901791168 Genvor, Inc. (OTCQB: GNVR) is a biotechnology company harnessing AI to generate novel peptides that deliver high-performance solutions across agriculture and human health. Powered by its proprietary BioCypher platform and patented peptides, Genvor is developing and intends to commercialize biological actives for crop protection and plant health alongside consumer-focused peptide solutions for recovery, performance, anti-aging, and daily wellness. Learn more at https://www.genvor.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted GNVR stock, in line with B2i Digital's practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $EVGN $PTN $RKDA $DYAI
1 · Reply
akts
akts Jul. 23 at 8:24 PM
$DYAI when do we realize the first $1 of revenue? 2027? Maybe? This is getting ridiculous. DYAI can’t survive on R&D grants forever.
1 · Reply
DylanGFM
DylanGFM Jul. 22 at 9:16 PM
$DYAI $SPY $STFS MF I KNEW IT!!! I WAS GOING TO COMMENT AND SAY WHEN THIS THING GETS VOLUME ITS GOIN TO GO STUPID AND IT DID!!!
1 · Reply
ParkerTradesX
ParkerTradesX Jul. 22 at 4:30 PM
Healthcare Takes the Stage: Massive 790% Breakout One of the fastest ways to build wealth is catching momentum as high-beta names crush 52-week highs. Healthcare stole the show today: $CPHI | Surges +790% as NYSE flags unusual activity $GREE | Ripping +37% past resistance $DYAI | Surges +21% on volume expansion $FEIM | Steady momentum up +20% Volatility creates opportunity. I shared these breakout setups before, but you weren't following me yet. You're here now. The next execution alert is coming soon. Head to my profile.
0 · Reply
KUMO2026
KUMO2026 Jul. 22 at 2:00 PM
$DYAI short off algo trap 1.60
0 · Reply
StockScanners
StockScanners Jul. 22 at 2:15 AM
$DYAI keep watch if this holds above
0 · Reply
Hdawg1YOLO
Hdawg1YOLO Jul. 22 at 2:00 AM
Eyes on $HELP and $$DYAI for tomorrow
0 · Reply
MovingFast77
MovingFast77 Jul. 21 at 11:18 PM
$DYAI This is how you do it. Trading buying #smx #gopro many others watch smx super low float of 600K history of running
0 · Reply
Latest News on DYAI
Dyadic International regains compliance with Nasdaq

2026-07-24T11:45:16.000Z - 7 days ago

Dyadic International regains compliance with Nasdaq


Dyadic International allowed claims by Japan Patent Office

2026-06-29T11:40:31.000Z - 4 weeks ago

Dyadic International allowed claims by Japan Patent Office


Dyadic International Transcript: AGM 2026

Jun 18, 2026, 10:00 AM EDT - 6 weeks ago

Dyadic International Transcript: AGM 2026


Dyadic International Proxy statement: Proxy filing

Jun 18, 2026, 8:00 AM EDT - 6 weeks ago

Dyadic International Proxy statement: Proxy filing


Dyadic International Slides: Investor presentation

May 19, 2026, 7:00 AM EDT - 2 months ago

Dyadic International Slides: Investor presentation


Dyadic International Earnings Call Transcript: Q1 2026

May 13, 2026, 5:00 PM EDT - 2 months ago

Dyadic International Earnings Call Transcript: Q1 2026


Dyadic International Earnings release: Q1 2026

May 13, 2026, 5:00 PM EDT - 2 months ago

Dyadic International Earnings release: Q1 2026


Dyadic International Quarterly report: Q1 2026

May 13, 2026, 5:00 PM EDT - 2 months ago

Dyadic International Quarterly report: Q1 2026


Dyadic International Proxy statement: Proxy filing

May 12, 2026, 8:00 AM EDT - 2 months ago

Dyadic International Proxy statement: Proxy filing


Dyadic International Slides

May 1, 2026, 5:11 PM EDT - 3 months ago

Dyadic International Slides


Dyadic International Proxy statement: Proxy filing

May 1, 2026, 8:00 AM EDT - 3 months ago

Dyadic International Proxy statement: Proxy filing


Dyadic International Earnings Call Transcript: Q4 2025

Mar 25, 2026, 5:00 PM EDT - 4 months ago

Dyadic International Earnings Call Transcript: Q4 2025


Dyadic International Earnings release: Q4 2025

Mar 25, 2026, 5:00 PM EDT - 4 months ago

Dyadic International Earnings release: Q4 2025


Dyadic International Annual report: Q4 2025

Mar 25, 2026, 5:00 PM EDT - 4 months ago

Dyadic International Annual report: Q4 2025


Dyadic International, Fermbox Bio launch of RNase-Free

2026-03-04T12:23:22.000Z - 5 months ago

Dyadic International, Fermbox Bio launch of RNase-Free


Dyadic International reports Q3 EPS (6c), consensus (4c)

2025-11-12T22:30:23.000Z - 9 months ago

Dyadic International reports Q3 EPS (6c), consensus (4c)


Dyadic International Earnings Call Transcript: Q3 2025

Nov 12, 2025, 5:00 PM EST - 9 months ago

Dyadic International Earnings Call Transcript: Q3 2025


Dyadic International Earnings release: Q3 2025

Nov 12, 2025, 5:00 PM EST - 9 months ago

Dyadic International Earnings release: Q3 2025


Dyadic International Quarterly report: Q3 2025

Nov 12, 2025, 5:00 PM EST - 9 months ago

Dyadic International Quarterly report: Q3 2025


Dyadic International assumed with a Buy at H.C. Wainwright

2025-10-23T10:10:55.000Z - 10 months ago

Dyadic International assumed with a Buy at H.C. Wainwright


Dyadic International announces achievement of milestone payments

2025-10-06T12:50:17.000Z - 10 months ago

Dyadic International announces achievement of milestone payments


Dyadic International Transcript: Small-Cap Virtual Conference

Sep 18, 2025, 9:15 AM EDT - 11 months ago

Dyadic International Transcript: Small-Cap Virtual Conference


Dyadic International initiated with a Buy at Craig-Hallum

2025-09-08T11:20:43.000Z - 11 months ago

Dyadic International initiated with a Buy at Craig-Hallum


Dyadic to Present at Investor Conferences and BPI East

Sep 4, 2025, 9:00 AM EDT - 11 months ago

Dyadic to Present at Investor Conferences and BPI East


Dyadic International Earnings Call Transcript: Q2 2025

Aug 13, 2025, 5:00 PM EDT - 1 year ago

Dyadic International Earnings Call Transcript: Q2 2025


Dyadic International Quarterly report: Q2 2025

Aug 13, 2025, 5:00 PM EDT - 1 year ago

Dyadic International Quarterly report: Q2 2025


Dyadic International Earnings release: Q2 2025

Aug 13, 2025, 5:00 PM EDT - 1 year ago

Dyadic International Earnings release: Q2 2025


Dyadic International Slides: Investor Presentation

Aug 13, 2025, 4:00 PM EDT - 1 year ago

Dyadic International Slides: Investor Presentation


Dyadic International Earnings Call Transcript: Q1 2025

May 14, 2025, 5:00 PM EDT - 1 year ago

Dyadic International Earnings Call Transcript: Q1 2025


Dyadic International Quarterly report: Q1 2025

May 14, 2025, 5:00 PM EDT - 1 year ago

Dyadic International Quarterly report: Q1 2025


Dyadic International Earnings release: Q1 2025

May 14, 2025, 5:00 PM EDT - 1 year ago

Dyadic International Earnings release: Q1 2025


Dyadic International Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Dyadic International Proxy statement: Proxy Filing


Dyadic International Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Dyadic International Proxy statement: Proxy Filing


Dyadic to Present at World Vaccine Congress | Washington

Apr 16, 2025, 2:00 PM EDT - 1 year ago

Dyadic to Present at World Vaccine Congress | Washington


Dyadic International Earnings Call Transcript: Q4 2024

Mar 26, 2025, 5:00 PM EDT - 1 year ago

Dyadic International Earnings Call Transcript: Q4 2024


Dyadic International Annual report: Q4 2024

Mar 26, 2025, 5:00 PM EDT - 1 year ago

Dyadic International Annual report: Q4 2024


Dyadic International Earnings release: Q4 2024

Mar 26, 2025, 5:00 PM EDT - 1 year ago

Dyadic International Earnings release: Q4 2024


Dyadic to Attend Multiple Industry Events in March

Mar 6, 2025, 8:30 AM EST - 1 year ago

Dyadic to Attend Multiple Industry Events in March


Dyadic International Earnings Call Transcript: Q3 2024

Nov 12, 2024, 5:00 PM EST - 1 year ago

Dyadic International Earnings Call Transcript: Q3 2024


Dyadic International Earnings release: Q3 2024

Nov 12, 2024, 5:00 PM EST - 1 year ago

Dyadic International Earnings release: Q3 2024


Dyadic International Quarterly report: Q3 2024

Nov 12, 2024, 5:00 PM EST - 1 year ago

Dyadic International Quarterly report: Q3 2024


Dyadic International Earnings Call Transcript: Q2 2024

Aug 13, 2024, 5:00 PM EDT - 2 years ago

Dyadic International Earnings Call Transcript: Q2 2024


Dyadic International Quarterly report: Q2 2024

Aug 13, 2024, 5:00 PM EDT - 2 years ago

Dyadic International Quarterly report: Q2 2024


Dyadic International Earnings release: Q2 2024

Aug 13, 2024, 5:00 PM EDT - 2 years ago

Dyadic International Earnings release: Q2 2024


Dyadic to Attend Industry Events in June

May 30, 2024, 4:30 PM EDT - 2 years ago

Dyadic to Attend Industry Events in June


Dyadic International Earnings Call Transcript: Q1 2024

May 14, 2024, 5:00 PM EDT - 2 years ago

Dyadic International Earnings Call Transcript: Q1 2024


Dyadic International Quarterly report: Q1 2024

May 14, 2024, 5:00 PM EDT - 2 years ago

Dyadic International Quarterly report: Q1 2024


Dyadic International Earnings release: Q1 2024

May 14, 2024, 5:00 PM EDT - 2 years ago

Dyadic International Earnings release: Q1 2024


Dyadic to Attend Industry and Investor Events in May

May 8, 2024, 8:30 AM EDT - 2 years ago

Dyadic to Attend Industry and Investor Events in May


Dyadic International Proxy statement: Proxy Filing

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Dyadic International Proxy statement: Proxy Filing


Dyadic International Proxy statement: Proxy Filing

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Dyadic International Proxy statement: Proxy Filing


Dyadic International Earnings Call Transcript: Q4 2023

Mar 28, 2024, 5:00 PM EDT - 2 years ago

Dyadic International Earnings Call Transcript: Q4 2023


Dyadic International Annual report: Q4 2023

Mar 28, 2024, 5:00 PM EDT - 2 years ago

Dyadic International Annual report: Q4 2023


Dyadic International Earnings release: Q4 2023

Mar 28, 2024, 5:00 PM EDT - 2 years ago

Dyadic International Earnings release: Q4 2023


B2iDigital
B2iDigital Jul. 27 at 9:32 PM
Genvor, Inc. (OTCQB: $GNVR), a biotechnology company harnessing AI to generate novel peptides, said its proprietary antimicrobial peptides are being evaluated for their potential to address microbial challenges in sugar beet production, under the USDA Agricultural Research Service (ARS) Sustainable Sugar Beet Research Initiative. Genvor is a @B2iDigital Featured Company. See the company's profile at https://b2idigital.com/genvor-incorporated-1 As a collaborator, the company is contributing its antimicrobial peptides for evaluation against key sugar beet microbial targets: • USDA-ARS researchers will evaluate whether Genvor's antimicrobial peptides can inhibit key microbes involved in sugar beet root rot and in downstream sugar extraction • The work may generate data to inform future peptide-based crop protection strategies "Our work with collaborators has consistently demonstrated how much peptide science can contribute to agriculture," said Dr. Jesse Jaynes, Co-Founder of Genvor and the founding scientist behind the company's core peptide technologies. "Extending that collaboration into sugar beet lets us apply our peptides to a new set of microbial targets and continue advancing the design work that makes these tools more effective." Read the full release: https://genvor.com/press-releases/post?storyId=6174274901791168 Genvor, Inc. (OTCQB: GNVR) is a biotechnology company harnessing AI to generate novel peptides that deliver high-performance solutions across agriculture and human health. Powered by its proprietary BioCypher platform and patented peptides, Genvor is developing and intends to commercialize biological actives for crop protection and plant health alongside consumer-focused peptide solutions for recovery, performance, anti-aging, and daily wellness. Learn more at https://www.genvor.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted GNVR stock, in line with B2i Digital's practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $EVGN $PTN $RKDA $DYAI
1 · Reply
B2iDigital
B2iDigital Jul. 27 at 6:25 PM
Genvor, Inc. (OTCQB: $GNVR), a biotechnology company harnessing AI to generate novel peptides, said its proprietary antimicrobial peptides are being evaluated for their potential to address microbial challenges in sugar beet production, under the USDA Agricultural Research Service (ARS) Sustainable Sugar Beet Research Initiative. Genvor is a @B2iDigital Featured Company. See the company's profile at https://b2idigital.com/genvor-incorporated-1 As a collaborator, the company is contributing its antimicrobial peptides for evaluation against key sugar beet microbial targets: • USDA-ARS researchers will evaluate whether Genvor's antimicrobial peptides can inhibit key microbes involved in sugar beet root rot and in downstream sugar extraction • The work may generate data to inform future peptide-based crop protection strategies "Our work with collaborators has consistently demonstrated how much peptide science can contribute to agriculture," said Dr. Jesse Jaynes, Co-Founder of Genvor and the founding scientist behind the company's core peptide technologies. "Extending that collaboration into sugar beet lets us apply our peptides to a new set of microbial targets and continue advancing the design work that makes these tools more effective." Read the full release: https://genvor.com/press-releases/post?storyId=6174274901791168 Genvor, Inc. (OTCQB: GNVR) is a biotechnology company harnessing AI to generate novel peptides that deliver high-performance solutions across agriculture and human health. Powered by its proprietary BioCypher platform and patented peptides, Genvor is developing and intends to commercialize biological actives for crop protection and plant health alongside consumer-focused peptide solutions for recovery, performance, anti-aging, and daily wellness. Learn more at https://www.genvor.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted GNVR stock, in line with B2i Digital's practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $EVGN $PTN $RKDA $DYAI
1 · Reply
B2iDigital
B2iDigital Jul. 27 at 2:59 PM
Genvor, Inc. (OTCQB: $GNVR ), a biotechnology company harnessing AI to generate novel peptides, said its proprietary antimicrobial peptides are being evaluated for their potential to address microbial challenges in sugar beet production, under the USDA Agricultural Research Service (ARS) Sustainable Sugar Beet Research Initiative. Genvor is a @B2iDigital Featured Company. See the company's profile at https://b2idigital.com/genvor-incorporated-1 As a collaborator, the company is contributing its antimicrobial peptides for evaluation against key sugar beet microbial targets: • USDA-ARS researchers will evaluate whether Genvor's antimicrobial peptides can inhibit key microbes involved in sugar beet root rot and in downstream sugar extraction • The work may generate data to inform future peptide-based crop protection strategies "Our work with collaborators has consistently demonstrated how much peptide science can contribute to agriculture," said Dr. Jesse Jaynes, Co-Founder of Genvor and the founding scientist behind the company's core peptide technologies. "Extending that collaboration into sugar beet lets us apply our peptides to a new set of microbial targets and continue advancing the design work that makes these tools more effective." Read the full release: https://genvor.com/press-releases/post?storyId=6174274901791168 Genvor, Inc. (OTCQB: GNVR) is a biotechnology company harnessing AI to generate novel peptides that deliver high-performance solutions across agriculture and human health. Powered by its proprietary BioCypher platform and patented peptides, Genvor is developing and intends to commercialize biological actives for crop protection and plant health alongside consumer-focused peptide solutions for recovery, performance, anti-aging, and daily wellness. Learn more at https://www.genvor.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted GNVR stock, in line with B2i Digital's practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $EVGN $PTN $RKDA $DYAI
1 · Reply
akts
akts Jul. 23 at 8:24 PM
$DYAI when do we realize the first $1 of revenue? 2027? Maybe? This is getting ridiculous. DYAI can’t survive on R&D grants forever.
1 · Reply
DylanGFM
DylanGFM Jul. 22 at 9:16 PM
$DYAI $SPY $STFS MF I KNEW IT!!! I WAS GOING TO COMMENT AND SAY WHEN THIS THING GETS VOLUME ITS GOIN TO GO STUPID AND IT DID!!!
1 · Reply
ParkerTradesX
ParkerTradesX Jul. 22 at 4:30 PM
Healthcare Takes the Stage: Massive 790% Breakout One of the fastest ways to build wealth is catching momentum as high-beta names crush 52-week highs. Healthcare stole the show today: $CPHI | Surges +790% as NYSE flags unusual activity $GREE | Ripping +37% past resistance $DYAI | Surges +21% on volume expansion $FEIM | Steady momentum up +20% Volatility creates opportunity. I shared these breakout setups before, but you weren't following me yet. You're here now. The next execution alert is coming soon. Head to my profile.
0 · Reply
KUMO2026
KUMO2026 Jul. 22 at 2:00 PM
$DYAI short off algo trap 1.60
0 · Reply
StockScanners
StockScanners Jul. 22 at 2:15 AM
$DYAI keep watch if this holds above
0 · Reply
Hdawg1YOLO
Hdawg1YOLO Jul. 22 at 2:00 AM
Eyes on $HELP and $$DYAI for tomorrow
0 · Reply
MovingFast77
MovingFast77 Jul. 21 at 11:18 PM
$DYAI This is how you do it. Trading buying #smx #gopro many others watch smx super low float of 600K history of running
0 · Reply
topstockalerts
topstockalerts Jul. 21 at 4:24 PM
$DYAI keep an eye on it
1 · Reply
TruthTooPower
TruthTooPower Jul. 21 at 3:45 PM
$DYAI!!! JBAFFS They Will!!! Go Over $25!!!!!
1 · Reply
Jbaffs
Jbaffs Jul. 21 at 3:41 PM
$DYAI they announce a $10M contract, stock gaps above $@/share. They do $50M in annual rev's I estimate they earn $1/share. Stock would go hyperbolic, over $25/share earning a $1.
1 · Reply
topstockalerts
topstockalerts Jul. 21 at 2:49 PM
Top Gainers PT2 $HIHO $GREE $JUNS $DYAI $AEHR
0 · Reply
Stock_Catcher
Stock_Catcher Jul. 21 at 2:28 PM
$DYAI $DFNS both perking
0 · Reply
BullButter23
BullButter23 Jul. 21 at 2:18 PM
$DYAI Above $2 this week. 💪🏻
0 · Reply
phd101
phd101 Jul. 21 at 2:16 PM
$DYAI watch
0 · Reply
RobWondo
RobWondo Jul. 21 at 1:36 AM
0 · Reply
TruthTooPower
TruthTooPower Jul. 17 at 12:19 PM
$DYAI??? ?????????????????????
2 · Reply
StreetwiseReports
StreetwiseReports Jul. 16 at 11:12 PM
Bullish Charts and Commercial Breakthroughs For Florida Biomanufacturer Could Fuel Upwards Valuation https://ow.ly/K0QB50ZoFxI Technical Analyst Stewart Thomson takes a look at Dyadic International Inc. ( $DYAI ) as it secures strategic partnerships in the human and animal health, food technology, cell culture media, and industrial enzyme sectors.
0 · Reply
PeterJPL
PeterJPL Jul. 15 at 8:17 AM
🔎 Wick Fill Watchlist A wick fill setup is when price revisits a prior spike/wick area — this is only a watchlist idea, not a buy signal. $SOBR – Score 105/100 | target area $1.57 ⚡ $LEDS – Score 90/100 | target area $2.66 👀 $DYAI – Score 88/100 | target area $1.34 🔍 $ACTU – Score 85/100 | target area $1.95 📊 $SHPH – Score 80/100 | target area $6.00 📈 Key now: volume confirmation, clean liquidity, and controlled dips. No need to chase vertical candles.
0 · Reply
StockScanners
StockScanners Jul. 15 at 4:14 AM
$DYAI keep watch if this holds above 1.16
0 · Reply